Cargando…
Rifampicin and anti-hypertensive drugs in chronic kidney disease: Pharmacokinetic interactions and their clinical impact
Patients on dialysis have an increased incidence of tuberculosis (TB). Rifampicin, a first-line antitubercular therapy (ATT) drug, is a potent inducer of hepatic cytochrome P450 (CYP). There is potential for pharmacokinetic interaction between rifampicin and anti-hypertensives that are CYP substrate...
Autores principales: | Agrawal, A., Agarwal, S. K., Kaleekal, T., Gupta, Y. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015508/ https://www.ncbi.nlm.nih.gov/pubmed/27795624 http://dx.doi.org/10.4103/0971-4065.176145 |
Ejemplares similares
-
Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole
por: Martin, Paul, et al.
Publicado: (2012) -
Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
por: Cui, Xiaoming, et al.
Publicado: (2022) -
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney
por: Asaumi, Ryuta, et al.
Publicado: (2022) -
Prescribing clozapine and rifampicin: clinical impact of their interaction
por: Parker, Caroline
Publicado: (2016) -
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children
por: Mukherjee, Aparna, et al.
Publicado: (2015)